These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 14567636)

  • 1. The effect of low concentrations of molecularly dispersed poly(vinylpyrrolidone) on indomethacin crystallization from the amorphous state.
    Crowley KJ; Zografi G
    Pharm Res; 2003 Sep; 20(9):1417-22. PubMed ID: 14567636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular dynamics simulation of amorphous indomethacin-poly(vinylpyrrolidone) glasses: solubility and hydrogen bonding interactions.
    Xiang TX; Anderson BD
    J Pharm Sci; 2013 Mar; 102(3):876-91. PubMed ID: 23280486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physical properties of solid molecular dispersions of indomethacin with poly(vinylpyrrolidone) and poly(vinylpyrrolidone-co-vinyl-acetate) in relation to indomethacin crystallization.
    Matsumoto T; Zografi G
    Pharm Res; 1999 Nov; 16(11):1722-8. PubMed ID: 10571278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raman and thermal analysis of indomethacin/PVP solid dispersion enteric microparticles.
    Fini A; Cavallari C; Ospitali F
    Eur J Pharm Biopharm; 2008 Sep; 70(1):409-20. PubMed ID: 18621516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of indomethacin crystallization in poly(vinylpyrrolidone) coprecipitates.
    Yoshioka M; Hancock BC; Zografi G
    J Pharm Sci; 1995 Aug; 84(8):983-6. PubMed ID: 7500284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase behavior of poly(vinylpyrrolidone) containing amorphous solid dispersions in the presence of moisture.
    Rumondor AC; Marsac PJ; Stanford LA; Taylor LS
    Mol Pharm; 2009; 6(5):1492-505. PubMed ID: 19634917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surface crystallization of indomethacin below Tg.
    Wu T; Yu L
    Pharm Res; 2006 Oct; 23(10):2350-5. PubMed ID: 16927184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Water vapor absorption into amorphous hydrophobic drug/poly(vinylpyrrolidone) dispersions.
    Crowley KJ; Zografi G
    J Pharm Sci; 2002 Oct; 91(10):2150-65. PubMed ID: 12226842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved physical stability of amorphous state through acid base interactions.
    Telang C; Mujumdar S; Mathew M
    J Pharm Sci; 2009 Jun; 98(6):2149-59. PubMed ID: 18837038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-plasticizing effect of amorphous indomethacin induced by specific intermolecular interactions with PVA copolymer.
    Ueda H; Aikawa S; Kashima Y; Kikuchi J; Ida Y; Tanino T; Kadota K; Tozuka Y
    J Pharm Sci; 2014 Sep; 103(9):2829-2838. PubMed ID: 24890320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced kinetic solubility profiles of indomethacin amorphous solid dispersions in poly(2-hydroxyethyl methacrylate) hydrogels.
    Sun DD; Ju TC; Lee PI
    Eur J Pharm Biopharm; 2012 May; 81(1):149-58. PubMed ID: 22233548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the molecular distribution of drugs in glassy solid dispersions at the nano-meter scale, using differential scanning calorimetry and gravimetric water vapour sorption techniques.
    van Drooge DJ; Hinrichs WL; Visser MR; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):220-9. PubMed ID: 16427226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Solubilities of crystalline drugs in polymers: an improved analytical method and comparison of solubilities of indomethacin and nifedipine in PVP, PVP/VA, and PVAc.
    Sun Y; Tao J; Zhang GG; Yu L
    J Pharm Sci; 2010 Sep; 99(9):4023-31. PubMed ID: 20607809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of wet milling process on the solid state of indomethacin and simvastatin.
    Sharma P; Denny WA; Garg S
    Int J Pharm; 2009 Oct; 380(1-2):40-8. PubMed ID: 19576976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of surface crystallisation of amorphous indomethacin particles in physical drug-polymer mixtures.
    Priemel PA; Laitinen R; Barthold S; Grohganz H; Lehto VP; Rades T; Strachan CJ
    Int J Pharm; 2013 Nov; 456(2):301-6. PubMed ID: 24012867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of albendazole crystallization in poly(vinylpyrrolidone) solid molecular dispersions.
    Kalaiselvan R; Mohanta GP; Manna PK; Manavalan R
    Pharmazie; 2006 Jul; 61(7):618-24. PubMed ID: 16889070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clarification of the Dissolution Mechanism of an Indomethacin/Saccharin/Polyvinylpyrrolidone Ternary Solid Dispersion by NMR Spectroscopy.
    Kosaka M; Higashi K; Nishimura M; Ueda K; Moribe K
    J Pharm Sci; 2020 Dec; 109(12):3617-3624. PubMed ID: 32931779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spectroscopic Investigation of the Formation and Disruption of Hydrogen Bonds in Pharmaceutical Semicrystalline Dispersions.
    Van Duong T; Reekmans G; Venkatesham A; Van Aerschot A; Adriaensens P; Van Humbeeck J; Van den Mooter G
    Mol Pharm; 2017 May; 14(5):1726-1741. PubMed ID: 28363028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions.
    Taylor LS; Zografi G
    Pharm Res; 1997 Dec; 14(12):1691-8. PubMed ID: 9453055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cryogenic grinding of indomethacin polymorphs and solvates: assessment of amorphous phase formation and amorphous phase physical stability.
    Crowley KJ; Zografi G
    J Pharm Sci; 2002 Feb; 91(2):492-507. PubMed ID: 11835208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.